Healthcare ❯ Clinical Trials

Drug Development

Oncology Regulatory Approval Precision Medicine AstraZeneca Treatment Efficacy RAS(ON) Inhibitors Phase Trials Global Health Impairment Loss FDA Approval Autoimmune Diseases Orforglipron HIV Treatments Boehringer Ingelheim Weight Management Antimicrobial Resistance GLP-1 Agonists Preclinical Research siRNA Therapy Antibody Therapy Pipeline Management COPD Treatments Anti-IL-11 Drugs Monoclonal Antibodies Therapeutic Applications Weight Loss Medications Ethical Concerns

Lilly Wins Exclusive License to Ascidian RNA Exon-Editing Platform for Kidney Diseases

The agreement hands later-stage development and commercialization to Lilly while expanding its genetic-medicine pipeline and funding Ascidian’s early research efforts.

Aristotle Flags Guardant Health as Key Q4 Contributor on Strong Results, Acquisition News

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Semnur Goes Public via Denali SPAC, Unveils $100 Million Bitcoin Stock Sale Plan

EU Regulators Back Uplizna as First Treatment for IgG4‑Related Disease